LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Develops ultrasound-mediated nonviral genetic medicines
Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas
Develops single-molecule PCR technology for genomics measurement
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
Decodes cellular networks to advance human health
Develops functional single-cell analysis tools and platforms for life science research
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Builds technologies for spatial biology and multi-omics innovation
Develops medicines targeting historically undruggable protein targets in cancer